Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Finishes Tough Year With Optimism For 2021

Executive Summary

J&J expects its medical device sales to begin growing rapidly by the middle of 2021 as the pandemic subsides.

You may also be interested in...



Despite Crisis In Some Areas, Analysts Do Not Expect Delta To Derail Recovery

Numbers of COVID-19 patients in the hospital are rising in many states and a few hospitals have been stretched to their limit, but data compiled by Credit Suisse suggests that the surgical capacity of US hospitals will stabilize in September.

J&J Continues Momentum In Second Quarter

Johnson & Johnson’s medical device sales were up nearly 60% year-over-year in the second quarter of 2021 while Abbott reported 51% growth in its device business, reflecting the recovery in procedure volumes since the worst days of the pandemic in mid-2020.

CMR Surgical Closes SoftBank-Led Funding Round Worth $600M

CMR Surgical has raised $600m to globally commercialize its Versius surgical robotics platform.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT143394

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel